Wellbiotec Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was KRW 3,065.44 million compared to KRW 534.28 million a year ago. Basic loss per share from continuing operations was KRW 46 compared to KRW 38 a year ago. Diluted loss per share from continuing operations was KRW 46 compared to KRW 38 a year ago. Basic loss per share was KRW 46 compared to KRW 9 a year ago.
For the nine months, sales was KRW 0.00002 million compared to KRW 0.00001 million a year ago. Net income was KRW 537.46 million compared to net loss of KRW 8,369.63 million a year ago. Basic earnings per share from continuing operations was KRW 8 compared to basic loss per share from continuing operations of KRW 186 a year ago. Diluted earnings per share from continuing operations was KRW 8 compared to diluted loss per share from continuing operations of KRW 186 a year ago. Basic earnings per share was KRW 8 compared to basic loss per share of KRW 161 a year ago.